en.Wedoany.com Reported - In March 2026, Brazil's medical cannabis imports reached a record high, with 23,199 import authorizations that month, a 60.1% increase compared to 14,485 in March 2025. This is the highest level since records began in 2015, according to a survey by Guarda-Chuva Cannect Cuida.
In the first quarter of 2026, the number of authorizations approved by the Brazilian Health Regulatory Agency (Anvisa) exceeded 61,000. Consulting firm Kaya estimates that Brazil's medical cannabis market will transact 1 billion reais in 2026. Allan Paiotti, CEO of Cannect, told CNN Brazil that the prevalence of issues such as anxiety, chronic pain, and insomnia has made cannabis a therapeutic alternative. As doctors become more knowledgeable about the therapy, their reluctance to prescribe decreases, leading to a corresponding increase in patient numbers. Research shows that the main motivations for Brazilians seeking this therapy include three categories: anxiety at 38.5%, chronic pain at 25.4%, and insomnia at 13.5%.
Allan Paiotti noted that Anvisa-approved cultivation regulations have driven market growth. Standardized cultivation, judicial rulings, and the provision of treatment in public networks by states all help reduce prejudice and boost public confidence. Personal imports dominate the use of cannabidiol products. Between 2015 and 2025, over 660,000 personal import authorizations were recorded. Currently, 49 products from 24 companies have been approved by Anvisa and are available for sale in pharmacies. Allan Paiotti said that more doctors and patients are beginning to explore medical cannabis therapy, and positive word-of-mouth and media coverage are accelerating the spread of treatment. However, cultural challenges still limit market growth, which must be overcome through increased awareness. He further emphasized that advancing cannabis treatment requires personalization, tailoring plans to individual patient differences to improve treatment efficacy and safety.
This article is compiled by Wedoany. All AI citations must indicate the source as "Wedoany". If there is any infringement or other issues, please notify us promptly, and we will modify or delete it accordingly. Email: news@wedoany.com
